Dow Up1.30% Nasdaq Up0.37%

Echo Therapeutics, Inc. (ECTE)

0.58 0.01(2.17%) Oct 30, 3:57PM EDT
ProfileGet Profile for:
Echo Therapeutics, Inc.
8 Penn Center
1628 JFK Boulevard
Philadelphia, PA 19103
United States - Map
Phone: 215-717-4100

Index Membership:N/A
Industry:Drug Manufacturers - Major
Full Time Employees:28

Business Summary 

Echo Therapeutics, Inc. is engaged in the development of transdermal skin permeation and diagnostic medical devices. It is developing Symphony CGM system (Symphony), a needle-free wireless continuous glucose monitoring system for use in hospital critical care units; and Symphony SkinPrep system, a component of its Symphony for enhanced skin permeation that enables extraction of analytes, such as glucose. The company is also engaged in the development Durhalieve, an AzoneTS formulation of triamcinolone acetonide that has completed Phase III clinical trials for the treatment of corticosteroid-responsive dermatoses. It has a licensing agreement with Ferndale Pharma Group, Inc. to develop, market, sell, and distribute Prelude SkinPrep system for skin preparation prior to the application of topical anesthetics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community; a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, use, market, import, and sell Symphony for continuous glucose monitoring for use by medical facilities and/or individual consumers in South Korea; and a license, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd. The company was founded in 1989 and is headquartered in Philadelphia, Pennsylvania.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Echo Therapeutics, Inc.

Key Executives 
Ms. Kimberly A. Burke J.D., 40
Acting Chief Exec. Officer, Chief Compliance Officer, Sr. VP and Gen. Counsel
Dr. Joseph Kost D.Sc., 67
Co-Founder and Chief Scientific Officer
Mr. Charles T. Bernhardt CPA, M.B.A., 53
Interim Chief Financial Officer
Mr. Marshall D. Deweese ,
Sr. VP of Operations
Christine H. Olimpio ,
Director of Investor Relations & Corp. Communications
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders